Patients with pneumonia from Covid 19 with at least one of the following comorbidities:
Hypertension
Obesity and/or type 2 diabetes
Cardiovascular disease
Chronic obstructive lung disease

Without any of the following comorbidities

Pneumonia, Viral

Hypertension

Diabetes Mellitus

Obesity

Cardiovascular Diseases

Obstructive Lung Disease

Fondazione Policlinico Universitario A. Gemelli IRCCS

Prognostic Factors Keeping Track for COVID-19 Pneumonia

Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

the efficacy of different pharmaceutical treatment against Covid-19

liver, kidney or multiorgan failure, cardiac failure

Geltrude Mingrone

Associate Professor of Internal Medicine

Catholic University of the Sacred Heart

Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment

Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment

Acute Myocardial Infarction

Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy

Bezafibrate

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction

PT-Fibrinogen HS Plus kit (Beckman Coulter, Brea, CA) to determine prothrombin time and fibrinogen and to evaluate extrinsic pathway of coagulation in citrated human plasma using an auto-analyzer ACL-800 (Cobas, Roche Diagnostics, Indianapolis, IN) where fibrinogen levels are determined through turbidimetry.

Concentration of cytokines (IL-8, IL-1β, IL-6, IL-10, TNF e IL-12) measured by ELISA system (Biosource)

angina, reinfarction, heart failure, death, and combined endpoints

Any side effect that comes with the intake of bezafibrate

anaphylaxis/triglyceride

Prognostic Factors Keeping Track for COVID-19 Pneumonia

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

PIoglitazone for PrEvention of Restenosis in Diabetic Patients

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird